Conference Correspondent

Chimeric antigen receptor (CAR) T-cell therapy is an immunotherapeutic approach used in the treatment of various hematologic malignancies. CAR T-cell therapy utilizes gene transfer to reprogram the patient’s own T-cells to recognize and target tumor-associated antigens. Although groundbreaking and incredibly efficacious, CAR T-cell therapy has serious side effects that require prompt identification and intervention. Read More ›

Chimeric antigen receptor (CAR) T-cell therapy is considered a living drug. The patient’s own T-cells are genetically engineered to express CARs that recognize tumor-associated antigens. CAR T-cell therapy has proved efficacious in various hematologic malignancies, and is promising in solid tumors. Read More ›

The immunotherapeutic landscape is dynamic and rapidly evolving. Immunomodulating therapies have proved effective in enhancing overall patient survival and inducing highly durable tumor responses. In this exciting and rapidly progressing setting, there is significant need for biosafety procedures to prevent unacceptable exposures. Read More ›

Immunotherapy represents a groundbreaking advance in the care of cancer patients. It modulates the body’s immune system to promote tumor destruction, and is now considered the fourth pillar of cancer treatment. Immunotherapeutic agents are associated with higher rates of immune-related adverse events that require immediate identification and intervention to prevent treatment cessation or fatal consequences. Read More ›

Immunotherapy represents a revolutionary advance in the care of cancer patients, and is now considered the fourth pillar of cancer treatment. Immunomodulating agents promote tumor destruction and enhance patient survival. They also result in a higher incidence of immune-related adverse events that require prompt recognition for effective management. Read More ›

Nivolumab is an immune checkpoint inhibitor proved to extend survival in patients with metastatic melanoma, non–small-cell lung cancer (NSCLC), and renal-cell carcinoma (RCC). When patients receive nivolumab combined with ipilimumab, they experience higher tumor response rates and increased progression-free survival. Patients receiving combined immunotherapeutic agents experience higher rates of immune-related adverse events compared with patients receiving monotherapy. Read More ›

The open-label, international, multicenter, multinational, phase 2 SUMMIT trial explored the efficacy and safety of neratinib monotherapy in patients with HER2-mutant metastatic breast cancer (MBC), and neratinib in combination with fulvestrant in patients with estrogen receptor (ER)-positive and HER2-positive MBC. Read More ›

Trastuzumab is a monoclonal antibody used for the treatment of HER2-positive breast cancer. Despite the efficacy of trastuzumab in the adjuvant setting, 1 in 4 patients experience disease recurrence. Neratinib is a potent, irreversible, pan-HER tyrosine kinase inhibitor that can combat mechanisms of disease escape and recurrence experienced with other HER2-targeted therapies. Read More ›

Educating Your Patients About Daratumumab
Leslie Lauersdorf insist that it's vital to inform your patients about what's involved in beginning daratumumab treatments, especially because of the lengthy chair time. Read More ›

How to Handle Survivorship Care for Multiple Myeloma
Tiffany Richards insists on the importance of survivorship care in patients with multiple myeloma and explains how to make sure patients stay as healthy as possible for as long as possible. Read More ›

Page 5 of 32


Subscribe to The Oncology Nurse-APN/PA

To sign up for our newsletter or print publications, enter your contact information below.

I'd like to receive: